Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Liabilities and Shareholders Equity: 2019-2025

Historic Liabilities and Shareholders Equity for Revolution Medicines (RVMD) over the last 6 years, with Sep 2025 value amounting to $2.3 billion.

  • Revolution Medicines' Liabilities and Shareholders Equity rose 27.73% to $2.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $9.6 billion, marking a year-over-year increase of 27.36%. This contributed to the annual value of $2.6 billion for FY2024, which is 24.09% up from last year.
  • According to the latest figures from Q3 2025, Revolution Medicines' Liabilities and Shareholders Equity is $2.3 billion, which was down 7.31% from $2.4 billion recorded in Q2 2025.
  • In the past 5 years, Revolution Medicines' Liabilities and Shareholders Equity ranged from a high of $2.6 billion in Q4 2024 and a low of $632.8 million during Q2 2022.
  • Its 3-year average for Liabilities and Shareholders Equity is $1.8 billion, with a median of $1.9 billion in 2024.
  • Per our database at Business Quant, Revolution Medicines' Liabilities and Shareholders Equity decreased by 18.25% in 2022 and then skyrocketed by 153.93% in 2023.
  • Quarterly analysis of 5 years shows Revolution Medicines' Liabilities and Shareholders Equity stood at $738.0 million in 2021, then increased by 10.02% to $811.9 million in 2022, then soared by 153.93% to $2.1 billion in 2023, then rose by 24.09% to $2.6 billion in 2024, then climbed by 27.73% to $2.3 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $2.3 billion for Q3 2025, versus $2.4 billion for Q2 2025 and $2.4 billion for Q1 2025.